PharmacovigilanceOfficial
Commission grants marketing authorisation for Revolution Medicines' daraxonrasib product Rasonque
🇪🇺 European Commission (Union Register) · Mon 16 Nov 2026
The European Commission has authorised Rasonque (daraxonrasib) for Revolution Medicines Netherlands B.V., though the Union Register entry does not state the indication or any conditions.
The European Commission has granted a new marketing authorisation for Rasonque, whose active substance is daraxonrasib, to Revolution Medicines Netherlands B.V. The authorisation was issued through Commission Decision (2026) 8340 of 16 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Official source: European Commission (Union Register) ↗
Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.
More Pharmacovigilance
All →
Pleasanton drug discovery firm Cyion to pay $528,336 over alleged False Claims Act grant violations
🇺🇸 HHS OIG · Mon 16 Nov 2026
Real4Reg final symposium at Infarmed showcases real-world data studies and free training
🇵🇹 INFARMED · Mon 16 Nov 2026
Baltic paper-free leaflet project to continue after 2026 with Commission's backing
🇪🇪 Ravimiamet · Mon 16 Nov 2026
Medline details repair and replace programme for recalled beds, rails, mattresses and accessories
🇺🇸 FDA MedWatch · Fri 13 Nov 2026
PRAC publishes final EU-language translations of phenobarbital product information in targeted signal procedure
🇪🇺 EMA · PRAC · Fri 13 Nov 2026
EMA page on veterinary signal management details phenobarbital review and updated MAH templates
🇪🇺 EMA · PRAC · Fri 13 Nov 2026